Catching cancer by the tail: new perspectives on the use of kinase inhibitors.
In this issue of Clinical Cancer Research, London and colleagues evaluate a small molecule multiple-targeted tyrosine kinase inhibitor in dogs with c-kit driven skin cancer. The study represents another example of opportunities to include pet dogs in studies that improve our understanding of human cancer biology and therapy.
Khanna
Chand
C
Center for Cancer Research, Comparative Oncology Program, and Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA. khannac@mail.nih.gov
Gordon
Ira
I
D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D012515:Mast-Cell Sarcoma / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D007211:Indoles; D011758:Pyrroles; C464577:toceranib phosphate; D020794:Receptor Protein-Tyrosine Kinases